Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2-CTLs for Mild to Moderate COVID-19
NCT04896606Phase 2Recruiting
- Sponsor
- New York Medical College
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by New York Medical College. Primary endpoint: Incidence of adverse events at 12 weeks. Started Sep 2021; status: recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04896606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896606.